Vaccines against bacterial meningitis.

Meningitis remains an important cause of morbidity and mortality among children >5 years of age and is especially prevalent in developing countries. Effective routine immunization against Hib, pneumococcus and serogroupC meningococcus has had a significant impact on both invasive disease and carriage caused by these encapsulated bacteria. The major challenge in prevention of meningitis remains the delivery of vaccines worldwide, especially to resource-poor regions with the greatest disease burden.

[1]  C. F. von Reyn,et al.  New vaccines for the prevention of tuberculosis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Mark A. Miller,et al.  Evaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa. , 1999, The Pediatric infectious disease journal.

[3]  D. Kasper,et al.  Conjugate vaccines against group B Streptococcus types IV and VII. , 2002, The Journal of infectious diseases.

[4]  P. Heath,et al.  Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. , 1998, The Pediatric infectious disease journal.

[5]  E. Zell,et al.  Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. , 1993, JAMA.

[6]  J. Boslego,et al.  Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. , 1995, Vaccine.

[7]  R. George,et al.  Pneumococcal bacteraemia and meningitis in England and Wales, 1993 to 1995. , 1998, Communicable disease and public health.

[8]  M. Lipsitch.  Interpreting results from trials of pneumococcal conjugate vaccines: a statistical test for detecting vaccine-induced increases in carriage of nonvaccine serotypes. , 2000, American journal of epidemiology.

[9]  D. Kasper,et al.  Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. , 1996, The Journal of clinical investigation.

[10]  R. Schneerson,et al.  Persistence of serum antibodies elicited by Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infants vaccinated at 3, 5 and 12 months of age. , 1991, The Pediatric infectious disease journal.

[11]  F. Michon,et al.  Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates. , 1997, The Journal of infectious diseases.

[12]  J. Poolman,et al.  Alternative vaccine strategies to prevent serogroup B meningococcal diseases. , 2001, Vaccine.

[13]  E. Tuomanen,et al.  Role of Novel Choline Binding Proteins in Virulence of Streptococcus pneumoniae , 2000, Infection and Immunity.

[14]  M. Achtman,et al.  Serogroup W135 meningococcal disease in Hajj pilgrims , 2000, The Lancet.

[15]  T. Popović,et al.  Distribution of Neisseria meningitidisSerogroup B Serosubtypes and Serotypes Circulating in the United States , 2000, Journal of Clinical Microbiology.

[16]  J. Riou,et al.  A predictable comeback: the second pandemic of infections caused by Neisseria meningitidis serogroup A subgroup III in Africa, 1995. , 1996, Bulletin of the World Health Organization.

[17]  M. Horwitz,et al.  Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D. Kasper,et al.  Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. , 2000, The Journal of infectious diseases.

[19]  H. McShane,et al.  Enhanced Immunogenicity of CD4+ T-Cell Responses and Protective Efficacy of a DNA-Modified Vaccinia Virus Ankara Prime-Boost Vaccination Regimen for Murine Tuberculosis , 2001, Infection and Immunity.

[20]  E. Lewis,et al.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. , 2000, The Pediatric infectious disease journal.

[21]  J. Venter,et al.  Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. , 2000, Science.

[22]  J. Emerson,et al.  Fifteen years of experience with bacterial meningitis. , 1999, The Pediatric infectious disease journal.

[23]  E. Mulholland.  Conjugate pneumococcal vaccines: an overview , 2000, The Medical journal of Australia.

[24]  L. van Alphen,et al.  Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. , 2000, Vaccine.

[25]  S. Salzberg,et al.  Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. , 2000, Science.

[26]  C. Rosenow,et al.  Contribution of novel choline‐binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae , 1997, Molecular microbiology.

[27]  E. Miyaji,et al.  Expression and characterization of cholera toxin B-pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CTB-PsaA to induce humoral immune response in mice. , 2004, Biochemical and biophysical research communications.

[28]  D. Goldblatt,et al.  Hospital admissions in children due to pneumococcal pneumonia in England. , 1998, The Journal of infection.

[29]  M. Lipsitch.  Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. , 1999, Emerging infectious diseases.

[30]  P. Fine.  The BCG story: lessons from the past and implications for the future. , 1989, Reviews of infectious diseases.

[31]  E. Moxon,et al.  The genetic basis of the phase variation repertoire of lipopolysaccharide immunotypes in Neisseria meningitidis. , 1999, Microbiology.

[32]  M. Taha,et al.  Neisseria meningitidis Serogroups W135 and A Were Equally Prevalent among Meningitis Cases Occurring at the End of the 2001 Epidemics in Burkina Faso and Niger , 2002, Journal of Clinical Microbiology.

[33]  I. Feavers,et al.  Neisseria lactamica Protects against Experimental Meningococcal Infection , 2002, Infection and Immunity.

[34]  S. Funnell,et al.  Recombinant Neisseria meningitidis Transferrin Binding Protein A Protects against Experimental Meningococcal Infection , 2001, Infection and Immunity.

[35]  H. Peltola.  Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. , 2000, Clinical microbiology reviews.

[36]  T. Popović,et al.  Distribution of Neisseria meningitidis Serogroup B Serosubtypes and Serotypes Circulating in the United States , 2000 .

[37]  Elizabeth Miller,et al.  Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction , 2004, The Lancet.

[38]  B. McPherson,et al.  Sequelae of epidemic meningococcal meningitis in Africa. , 1988, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[39]  A. Pollard,et al.  Vaccine prevention of meningococcal disease, coming soon? , 2001, Vaccine.

[40]  C. Hart,et al.  Meningococcal Disease , 1974, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[41]  B. Greenwood,et al.  Importance of enteric bacteria as a cause of pneumonia, meningitis and septicemia among children in a rural community in The Gambia, West Africa , 1994, The Pediatric infectious disease journal.

[42]  S. Lockhart,et al.  Efficacy of a pneumococcal conjugate vaccine against acute otitis media. , 2001, The New England journal of medicine.

[43]  P. Dumas,et al.  Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals. , 1993, Vaccine.

[44]  D. Heymann,et al.  Meningococcal vaccine in sub-Saharan Africa , 1997, The Lancet.

[45]  J. McVernon,et al.  Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis , 2003, The Lancet.

[46]  M. Criado,et al.  In vitro induction of memory-driven responses against Neisseria meningitidis by priming with Neisseria lactamica. , 2002, Vaccine.

[47]  G. Grandi,et al.  Antibacterial vaccine design using genomics and proteomics. , 2001, Trends in biotechnology.

[48]  E. Lamani,et al.  Characterization of Selected Strains of Pneumococcal Surface Protein A* , 2001, The Journal of Biological Chemistry.

[49]  D. Crook,et al.  Antibody persistence and Haemophilus influenzae type b carriage after infant immunisation with PRP-T , 1997, Archives of disease in childhood.

[50]  P. Anderson,et al.  Serum antibodies in six-year-old children vaccinated in infancy with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. , 1996, The Pediatric infectious disease journal.

[51]  R. Lathigra,et al.  Identification and Characterization of a Novel Family of Pneumococcal Proteins That Are Protective against Sepsis , 2001, Infection and Immunity.

[52]  O. Levine,et al.  Introduction of Hib conjugate vaccines in the non-industrialized world: experience in four 'newly adopting' countries. , 1999, Vaccine.

[53]  J. Paton,et al.  Additive Attenuation of Virulence ofStreptococcus pneumoniae by Mutation of the Genes Encoding Pneumolysin and Other Putative Pneumococcal Virulence Proteins , 2000, Infection and Immunity.

[54]  N. Cadieux,et al.  Bactericidal and Cross-Protective Activities of a Monoclonal Antibody Directed against Neisseria meningitidis NspA Outer Membrane Protein , 1999, Infection and Immunity.

[55]  S. Black,et al.  Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine , 2001, The Pediatric infectious disease journal.

[56]  S. Salzberg,et al.  Complete Genome Sequence of a Virulent Isolate of Streptococcus pneumoniae , 2001, Science.

[57]  Christoph M Tang,et al.  Functional genomics of Neisseria meningitidis pathogenesis , 2000, Nature Medicine.

[58]  W. Scheld,et al.  New perspectives on bacterial meningitis. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[59]  G. Rougon,et al.  Evidence for autoimmune antibodies directed against embryonic neural cell adhesion molecules (N-CAM) in patients with group B meningitis , 1990, Journal of Neuroimmunology.

[60]  B. Greenwood,et al.  Manson Lecture. Meningococcal meningitis in Africa. , 1999, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[61]  G. Rougon,et al.  Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. , 2004, Vaccine.

[62]  K. O'Brien,et al.  Pneumococcal conjugate vaccines: proceedings from an interactive symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. , 2003, Vaccine.

[63]  Elliot J. Lefkowitz,et al.  Genome of the Bacterium Streptococcus pneumoniae Strain R6 , 2001, Journal of bacteriology.

[64]  K. Cartwright,et al.  Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6-8 October, 2000. , 2001, Vaccine.

[65]  W. Heyward,et al.  Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group. , 1990, The New England journal of medicine.

[66]  B. Greenwood,et al.  The epidemiology of pneumococcal infection in children in the developing world. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[67]  L. Harrison,et al.  Invasive meningococcal disease in adolescents and young adults. , 2001, JAMA.

[68]  M. Lipsitch,et al.  Competition among Streptococcus pneumoniae for intranasal colonization in a mouse model. , 2000, Vaccine.

[69]  P. Dull,et al.  Meningococcal disease and vaccines. , 2001, Pediatric annals.

[70]  S. Black,et al.  Efficacy of pneumococcal conjugate vaccines in large scale field trials , 2000, The Pediatric infectious disease journal.

[71]  B. Spratt,et al.  Meningococcal conjugate vaccines: new opportunities and new challenges , 1999, The Lancet.

[72]  D. Simon,et al.  Large-scale identification of virulence genes from Streptococcus pneumoniae. , 1998, Infection and immunity.

[73]  S. Obaro,et al.  Confronting the pneumococcus: a target shift or bullet change? , 2000, Vaccine.

[74]  S. Black,et al.  Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. , 1999, The Pediatric infectious disease journal.

[75]  S. Cole,et al.  Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis , 2003, Nature Medicine.

[76]  T. Brewer.  Preventing tuberculosis with bacillus Calmette-Guérin vaccine: a meta-analysis of the literature. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[77]  C S Berkey,et al.  Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. , 1994, JAMA.

[78]  M. Ramsay,et al.  The epidemiology of acute meningitis in children in England and Wales , 2003, Archives of disease in childhood.

[79]  Edward C. Holmes,et al.  Distribution of Surface Protein Variants among Hyperinvasive Meningococci: Implications for Vaccine Design , 2004, Infection and Immunity.

[80]  E. Lewis,et al.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children , 2000, The Pediatric infectious disease journal.

[81]  P. Mäkelä,et al.  A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. , 1990, The New England journal of medicine.

[82]  Norazmi Mohd Nor,et al.  Approaches towards the development of a vaccine against tuberculosis: recombinant BCG and DNA vaccine. , 2004, Tuberculosis.

[83]  J. Eskola,et al.  Pneumococcal conjugate vaccines. , 1999, The Pediatric infectious disease journal.

[84]  J. Tappero,et al.  Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. , 1999, JAMA.

[85]  B. Barrell,et al.  Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491 , 2000, Nature.

[86]  G. Delogu,et al.  DNA Vaccine Combinations Expressing Either Tissue Plasminogen Activator Signal Sequence Fusion Proteins or Ubiquitin-Conjugated Antigens Induce Sustained Protective Immunity in a Mouse Model of Pulmonary Tuberculosis , 2002, Infection and Immunity.

[87]  Y. Guo,et al.  Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. , 1997, The Journal of infectious diseases.

[88]  G. Colditz,et al.  Relationship between bacille Calmette-Guérin (BCG) strains and the efficacy of BCG vaccine in the prevention of tuberculosis. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[89]  M. Lonetto,et al.  A functional genomic analysis of type 3 Streptococcus pneumoniae virulence , 2001, Molecular microbiology.

[90]  R. Hakenbeck,et al.  Mosaic Genes and Mosaic Chromosomes: Intra- and Interspecies Genomic Variation of Streptococcus pneumoniae , 2001, Infection and Immunity.

[91]  W. Britton,et al.  Coexpression of Interleukin-12 Chains by a Self-Splicing Vector Increases the Protective Cellular Immune Response of DNA and Mycobacterium bovis BCG Vaccines against Mycobacterium tuberculosis , 2002, Infection and Immunity.

[92]  Theresa M. Wizemann,et al.  Use of a Whole Genome Approach To Identify Vaccine Molecules Affording Protection against Streptococcus pneumoniae Infection , 2001, Infection and Immunity.

[93]  I. Feavers,et al.  Development of vaccines against meningococcal disease , 2002, The Lancet.

[94]  M. Maiden,et al.  Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination , 2002, The Lancet.

[95]  G. Bancroft,et al.  Characterization of Auxotrophic Mutants ofMycobacterium tuberculosis and Their Potential as Vaccine Candidates , 2001, Infection and Immunity.

[96]  J. Poolman.  Pneumococcal vaccine development , 2004, Expert review of vaccines.

[97]  S. Jaffar,et al.  Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H. influenzae type b among Gambian children. , 1998, The Journal of infectious diseases.

[98]  M. J. Jedrzejas.  Pneumococcal Virulence Factors: Structure and Function , 2001, Microbiology and Molecular Biology Reviews.

[99]  M. Leinonen,et al.  ANTIGENIC SIMILARITIES BETWEEN BRAIN COMPONENTS AND BACTERIA CAUSING MENINGITIS Implications for Vaccine Development and Pathogenesis , 1983, The Lancet.

[100]  M. Peitsch,et al.  Annotated draft genomic sequence from a Streptococcus pneumoniae type 19F clinical isolate. , 2001, Microbial drug resistance.

[101]  M. Ramsay,et al.  Changing patterns of invasive Haemophilus influenzae disease in England and Wales after introduction of the Hib vaccination programme , 1996, BMJ.